544 related articles for article (PubMed ID: 28689363)
1. Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors.
Parise CA; Caggiano V
Breast Cancer Res Treat; 2017 Oct; 165(3):743-750. PubMed ID: 28689363
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
[TBL] [Abstract][Full Text] [Related]
3. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
[TBL] [Abstract][Full Text] [Related]
4. Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country.
Subramaniam S; Bhoo-Pathy N; Taib NA; Tan GH; See MH; Jamaris S; Ho GF; Looi LM; Yip CH
World J Surg; 2015 Oct; 39(10):2450-8. PubMed ID: 26138872
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
Parise CA; Bauer KR; Brown MM; Caggiano V
Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.
Ferguson NL; Bell J; Heidel R; Lee S; Vanmeter S; Duncan L; Munsey B; Panella T; Orucevic A
Breast J; 2013; 19(1):22-30. PubMed ID: 23240985
[TBL] [Abstract][Full Text] [Related]
7. Relationship of established risk factors with breast cancer subtypes.
McCarthy AM; Friebel-Klingner T; Ehsan S; He W; Welch M; Chen J; Kontos D; Domchek SM; Conant EF; Semine A; Hughes K; Bardia A; Lehman C; Armstrong K
Cancer Med; 2021 Sep; 10(18):6456-6467. PubMed ID: 34464510
[TBL] [Abstract][Full Text] [Related]
8. Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer.
Bauer K; Parise C; Caggiano V
BMC Cancer; 2010 May; 10():228. PubMed ID: 20492696
[TBL] [Abstract][Full Text] [Related]
9. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
10. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study.
Puig-Vives M; Sánchez MJ; Sánchez-Cantalejo J; Torrella-Ramos A; Martos C; Ardanaz E; Chirlaque MD; Perucha J; Díaz JM; Mateos A; Machón M; Marcos-Gragera R
Gynecol Oncol; 2013 Sep; 130(3):609-14. PubMed ID: 23747837
[TBL] [Abstract][Full Text] [Related]
11. Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival.
Jeon YW; Kang SH; Park MH; Lim W; Cho SH; Suh YJ
BMC Cancer; 2015 Nov; 15():865. PubMed ID: 26546331
[TBL] [Abstract][Full Text] [Related]
12. Differences in clinicopatholgic characteristics and risk of mortality between the triple positive and ER+/PR+/HER2- breast cancer subtypes.
Parise CA; Caggiano V
Cancer Causes Control; 2019 May; 30(5):417-424. PubMed ID: 30879205
[TBL] [Abstract][Full Text] [Related]
13. Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival.
Kobayashi N; Hikichi M; Ushimado K; Sugioka A; Kiriyama Y; Kuroda M; Utsumi T
Clin Transl Oncol; 2017 Oct; 19(10):1232-1240. PubMed ID: 28409323
[TBL] [Abstract][Full Text] [Related]
14. Lack of either estrogen or progesterone receptor expression is associated with poor survival outcome among luminal A breast cancer subtype.
Park S; Park BW; Kim TH; Jeon CW; Kang HS; Choi JE; Hwang KT; Kim IC
Ann Surg Oncol; 2013 May; 20(5):1505-13. PubMed ID: 23192228
[TBL] [Abstract][Full Text] [Related]
15. Disparities in the risk of the ER/PR/HER2 breast cancer subtypes among Asian Americans in California.
Parise C; Caggiano V
Cancer Epidemiol; 2014 Oct; 38(5):556-62. PubMed ID: 25172158
[TBL] [Abstract][Full Text] [Related]
16. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
[TBL] [Abstract][Full Text] [Related]
17. Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status.
Ma H; Lu Y; Malone KE; Marchbanks PA; Deapen DM; Spirtas R; Burkman RT; Strom BL; McDonald JA; Folger SG; Simon MS; Sullivan-Halley J; Press MF; Bernstein L
BMC Cancer; 2013 May; 13():225. PubMed ID: 23642215
[TBL] [Abstract][Full Text] [Related]
18. In modern times, how important are breast cancer stage, grade and receptor subtype for survival: a population-based cohort study.
Johansson ALV; Trewin CB; Fredriksson I; Reinertsen KV; Russnes H; Ursin G
Breast Cancer Res; 2021 Feb; 23(1):17. PubMed ID: 33526044
[TBL] [Abstract][Full Text] [Related]
19. Treatment and survival disparities by ethnicity in New Zealand women with stage I-III breast cancer tumour subtypes.
Lawrenson R; Lao C; Campbell I; Harvey V; Seneviratne S; Edwards M; Elwood M; Scott N; Kidd J; Sarfati D; Kuper-Hommel M
Cancer Causes Control; 2017 Dec; 28(12):1417-1427. PubMed ID: 29027594
[TBL] [Abstract][Full Text] [Related]
20. T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy.
Kaplan HG; Malmgren JA; Atwood M
Breast J; 2009; 15(5):454-60. PubMed ID: 19671105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]